Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion

Medical Abortion Clinical Trial

— MiMAC  

Official title:

Prospective Non Interventional Phase IV Multi-centre Canadian Study on the Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion Under 63 Days Gestation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04905251
• Other study ID #: LPI011
• Status: Recruiting
• Start date: February 22, 2022
• Est. completion date: December 30, 2023

Study information

• Verified date: August 2022
• Source: Linepharma International LTD
• Contact: Delphine JAQUET, MD PhD
• Phone: +33786299178
• Email: d.jaquet[@]linepharma-lab.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

National multi-center non interventional study aiming at investigating the effectiveness and safety of the combination mifepristone-misoprostol prescribed in Canada to women for medical termination of pregnancy at or before 63 days gestational age through a multi-center prospective non interventional study design.

Description:

Primary Objectives:

• Effectiveness of mifepristone-misoprostol for medical abortion at or prior to 63 days gestational age, defined as complete abortion without further intervention within 14 days of mifepristone administration

• Safety of mifepristone-misoprostol for medical abortion at or prior to 63 days gestational age, defined as the rate of significant Treatment Emergent Adverse Events (TEAE) as a composite outcome of the following events: 1. Hospital Admission; 2. Treatment in Emergency Room; 3. Blood Transfusion; 4. Infection requiring IV Antibiotics, Admission, or Surgical debridement; 5. Death; 6. Ongoing intrauterine pregnancy; 7. Ectopic pregnancy.

Secondary objectives:

• To determine the rate of ongoing pregnancy within 14 days after the administration of mifepristone

• To determine the rate of surgical aspiration performed at the follow-up and time since mifepristone administration

• To determine the reasons for surgical aspiration

• To evaluate the follow-up rate

• To evaluate the delay between the scheduled and actual treatment administration

• To determine the overall safety profile of mifepristone-misoprostol combination

• To evaluate the impact of the demographic characteristics (prescription site, region, gestational age) on effectiveness and safety

• To evaluate the impact of gestational age on effectiveness and safety

• To evaluate the impact of treatment self-administration on effectiveness and safety

• To evaluate the impact of the method and timing of determining gestational age on effectiveness and safety

Study population:

Study performed on a stratified sample of sequential participants (n=3,000) who fulfill trial selection criteria and provide informed consent across a range of clinical practices in Canada (n=30)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: December 30, 2023
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 16 Years to 55 Years

Eligibility

Inclusion criteria

Women who:

• request elective pregnancy termination in one of the sites participating into the study

• are prescribed mifepristone-misoprostol for this purpose

• provide informed consent to participate in the study.

Exclusion Criteria:

• Participant who is unable to understand or comply with Health Care Professional instructions or medical abortion regimen

• Participant who is unable or unwilling to provide written informed consent.

Related Conditions & MeSH terms

• Medical Abortion

Intervention

Drug:
• Mifepristone-Misoprostol
Non interventional design.

Locations

Country	Name	City	State
Canada	Women's Wellness Program and Sexual Services	Charlottetown	Prince Edward Island
Canada	Centennial Primary Care	Kentville	Nova Scotia
Canada	Manitoulin Health Centre	Mindemoya	Ontario
Canada	Family Planning Clinic, Moncton City Hospital	Moncton	New Brunswick
Canada	Mud Creek Medical	New Minas	Nova Scotia
Canada	Choice in Health Clinic	Toronto	Ontario
Canada	Women's College Hospital	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Linepharma International LTD

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness of mifepristone-misoprostol for medical abortion at or prior to 63 days of gestational age	Defined as complete abortion without further intervention within 14 days of mifepristone administration.	14 to 28 days
Primary	Safety of mifepristone-misoprostol for medical abortion at or prior to 63 days gestational age	Defined as the rate of significant Treatment Emergent Adverse Events (TEAE) as a composite outcome of the following events: 1. Hospital Admission; 2. Treatment in Emergency Room; 3. Blood Transfusion; 4. Infection requiring IV Antibiotics, Admission, or Surgical debridement; 5. Death; 6. Ongoing intrauterine pregnancy; 7. Ectopic pregnancy.	14 to 28 days
Secondary	Rate of ongoing pregnancy	Frequency of ongoing pregnancy documented at the first follow-up visit within 14 days after mifepristone administration. The method used to document the completion of abortion and the intervention proposed in case of ongoing pregnancy will also be recorded.	14 to 28 days
Secondary	Rate of surgical aspiration	Description of the frequency (n and percentage of surgical abortion)	14-28 days
Secondary	Reasons for surgical aspiration	Frequency of the following indications: Ongoing pregnancy, Persistent gestational sac, Retained products of conception, Severe bleeding , Pelvic pain, Suspicion of ectopic pregnancy, others	14-28 days
Secondary	Delay between the scheduled and actual treatment administration	Measure of the time (in days) between the date scheduled at the initial visit and the actual date of administration of mifepristone.; Measure of the time (in hour) between the actual administration of misoprostol and the actual administration of mifepristone.; Description of the rate of mifepristone administration after 63 weeks of gestational age	14 days
Secondary	Overall safety profile of mifepristone-misoprostol combination	Frequency of the following: TEAEs /Serious TEAEs (STEAEs) included in the composite criteria,; Hysterectomy, Asthma resistant to common drugs, Cardiovascular event, Skin rash, angioedema, anaphylaxis,, Seizure, Suicide,; Potential consequences of ongoing pregnancy exposed to mifepristone +/- misoprostol,; All other serious adverse events (SAEs) described by System, Organ, Class (SOC) and Preferred Term (PT) ,; All other TEAE described by SOC and PT	14-28 days
Secondary	Impact of the demographic characteristics on effectiveness and safety	Comparison of the rates of the primary effectiveness and safety endpoints according to the following stratified parameters: Health Care Professional's site: 1) Abortion Clinic 2) Hospital 3) Private practice 4) Other; Type of Health Care Professional: 1) Specialist, 2) General Practitioner, 3) Nurse, 4) Other; Participant location : rural vs. urban; Geographic area of the prescribing site according to Canadian province	14-28 days
Secondary	Impact of gestational age on effectiveness and safety	Comparison of the rates of the primary effectiveness and safety endpoints according to gestational age at the time of actual mifepristone administration according to the following stratification: = 35 days; 36-49 days; 50-63 days; > 63 days	14-28 days
Secondary	Impact of treatment self-administration on effectiveness and safety	Comparison of the rates of the primary effectiveness and safety endpoints according to the location at which mifepristone is taken: At the study site; At home	14-28 days
Secondary	Impact of the method and timing of determining gestational age on effectiveness and safety	Comparison of the rates of the primary effectiveness and safety endpoints according to the fact that ultra-sonography was performed (or not) to confirm gestational age and rule out ectopic pregnancy.; Description of the mean timing of gestational age determination by ultra-sonography (in weeks of amenorrhea) according to the primary endpoints (existence of complete abortion (yes/no) and of significant treatment emergent adverse event (yes/no)).	14-28 days
Secondary	Follow-up rate	The follow-up rate will be assessed up to 28 days after mifepristone administration by describing the rate of: Attendance at the in-person follow-up visit between 7 and 14 days after mifepristone administration; Attendance at a remote follow-up visit (phone call) up to 28 days after mifepristone administration; Loss to follow-up (inability to contact participant up to 28 days following mifepristone administration)	28 days